Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03019653 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT03019653: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT03019653 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03019653, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to look at kidney function and hormonal function in patients with a history of heart failure and kidney dysfunction, and to see how the use of a new drug, ANX-042, affects those functions.
Interventions
- DRUG Placebo
- DRUG ANX-042
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2017-01 |
| Est. Completion | 2024-09-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03019653
The ClinicalTrials.gov registry entry for NCT03019653 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03019653 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03019653 about?
NCT03019653 is a clinical study titled "Safety and Efficacy of ANX-042 in Human Cardiorenal Syndrome". The purpose of this study is to look at kidney function and hormonal function in patients with a history of heart failure and kidney dysfunction, and to see how the use of a new drug, ANX-042, affects those functions.
What is the current status of trial NCT03019653?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2017-01. Estimated completion is 2024-09-13.
What interventions are being tested in trial NCT03019653?
The interventions under investigation include: Placebo (DRUG), ANX-042 (DRUG).
Who is sponsoring clinical trial NCT03019653?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.